Presentation

XVIVO Perfusion is a medical technology company that develops optimised solutions for organ, tissue and cell preservation and perfusion in connection with transplantation. Founded in 1998 and headquartered in Gothenburg, Sweden, XVIVO also has a production site in Lund, Sweden and office in Denver, USA.

Recent highlights
In Q2, net sales amounted to 94.3M SEK (+59%). Organic growth amounted to 28% adjusted for currency effects.
In January, XVIVO’s innovative preservation technology was used in the world’s first ever successful heart xenotransplantation (pig to human). In the same month, XVIVO announced FDA 510(k) clearance for Kidney Assist Transport, a transportable organ perfusion system, which is XVIVO’s first regulatory cleared product for abdominal transplantation in the US. In February, XVIVO gained regulatory approval in China from NMPA for PERFADEX® Plus – the global gold standard for lung preservation. In March, XVIVO announced EU MDR certification for Kidney Assist Transport. In August, XVIVO entered into an agreement to acquire its Italian distributor to secure a unique business model.

Outlook
The company has defined 5 strategic areas for 2022-2026: (1) Become the global leader in the abdominal area, (2) Launch a market leading heart preservation system, (3) Increase penetration of machine perfusion, (4) Secure comprehensive reimbursement systems on important geographical markets, and (5) Develop China to become XVIVO’s second biggest market.